Federal Containment Level 2 license will
support testing and validation for studies and sale of natural
products
VANCOUVER, BC, March 14, 2022 /CNW/ - Numinus Wellness Inc.
("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a
mental healthcare company advancing innovative treatments and safe,
evidence-based psychedelic-assisted therapies, is pleased to
announce that its research lab, Numinus Bioscience, has been
approved by the Public Health Agency of Canada for a Containment Level 2 (CL2)
pathogens and toxins license, following upgrading of the facility.
The addition will contribute novel data on natural psychedelics,
presenting additional IP opportunities and another revenue driver
through contract research services.
With the license, Numinus Bioscience will begin the
following:
|
1)
|
Study of pathogens
and bacterial, fungal and microbial contaminants to identify
baseline markers and optimal growth environments for
Psilocybe mushrooms;
|
|
2)
|
Bioassay studies
using mammalian cell lines, to analyze the bioactivity of different
whole mushroom formulations that contain both psilocybin and other
psychedelic compounds;
|
|
3)
|
Pharmacokinetic (PK)
and pre-clinical studies using analysis of blood and other bodily
fluids, to investigate reactions in the human body to whole
mushrooms and other natural formulations.
|
"This biosecurity expansion will allow us to deeply understand
not only the mechanisms behind Psilocybe mushrooms and other
naturally occurring psychedelic materials but also their
interaction with the human body," said Sharan Sidhu, Science Officer and General
Manager, Numinus Bioscience. "By performing testing and validation
at a highly precise level, we will advance both our own IP
development of finished products and scaled production processes,
as well as contract services and sale of materials to research and
industry partners."
The license is in addition to Numinus Bioscience's existing
Controlled Drugs and Substances Dealer's License from Health Canada
and underscores Numinus' long-term strategy of establishing a
center of excellence for natural psychedelic research, including
extensive license amendments and investment into state-of-the-art
equipment such as the Orbitrap, which identifies metabolites in the
body and will play a key role in the PK and pre-clinical
studies.
"With this new license, Numinus is more committed than ever to
advancing psychedelic research from theory to practice," said
Payton Nyquvest, CEO and founder,
Numinus. "By investigating optimal growth, bioavailability and
pharmacokinetics, we are moving closer to developing therapeutics
at scale to support accessible psychedelic-assisted therapy."
About Numinus
Numinus Wellness helps people to heal and be well through the
development and delivery of innovative mental health care and
access to safe, evidence-based psychedelic-assisted therapies. The
Numinus model – including psychedelic production, research and
clinic care – is at the forefront of a transformation aimed at
healing rather than managing symptoms for depression, anxiety,
trauma, pain and substance use. At Numinus, we are leading the
integration of psychedelic-assisted therapies into mainstream
clinical practice and building the foundation for a healthier
society.
Learn more at numinus.com and follow us
on LinkedIn, Facebook, Twitter,
and Instagram.
Forward-Looking Statements
Statements and other
information contained in this press release about anticipated
future events constitute forward-looking statements.
Forward-looking statements are often, but not always, identified by
the use of words such as "seek", "anticipate", "believe", "plan",
"estimate", "expect" and "intend" and statements that an event
"may", "will", "should", "could" or "might" occur or other similar
expressions. Forward-looking statements are subject to risks and
uncertainties and other factors that could cause actual results to
differ materially from those contained in the forward-looking
statements. Forward-looking statements are based on estimates and
opinions of management at the date the statements are made. The
Company does not undertake any obligation to update forward-looking
statements even if circumstances or management's estimates or
opinions should change except as required by applicable laws.
Investors should not place undue reliance on forward-looking
statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/numinus-expands-natural-psychedelic-research-with-new-biosecurity-license-301501504.html
SOURCE Numinus Wellness Inc.
